Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
CardioVia
CardioVia Overview
CardioVia is a medical device company developing a system called ViaOne. ViaOne allows minimally invasive access to the outer surface of the heart (the pericardial space), which has been recognized as a promising entry route to treat prevalent cardiovascular diseases such as tamponade, effusion, and arrhythmias.
ViaOne is intended to ensure safe pericardial access in order to avoid complications and ensure procedural success. It aims to increase the physicians confidence during the procedure while providing safety and assurance to the patient.
The companys technology ensures that no needle is exposed to the heart at any time. The procedure is performed in a controlled and measured manner while synchronizing with the heartbeats, and the system allows penetration to the outer surface of the pericardial space without risk of puncturing the heart muscle.
CardioVia established a complete operating system in preclinical studies and is currently in the process of receiving regulatory approvals from the FDA and CE. In addition, the project has received funding from the European Unions Horizon 2020 research and innovation program under grant agreement number 868213.